Second Sight Medical (EYES) Prices 10M Share Offering at $5/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow, S&P open higher as upbeat earnings obscure Mideast jitters
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- DOJ reportedly preparing antitrust lawsuit against Live Nation, shares slide 9%
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
After-Hours Stock Movers 06/22: (SEAC) (SHAK) (CLNE) Higher; (GMTX) (EYES) (BSY) Lower (more...)
June 22, 2021 5:56 PM EDTAfter-Hours Stock Movers:
Gemini Therapeutics, Inc. (Nasdaq: GMTX) 35.7% LOWER; announced initial data from its Phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry AMD. ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant human complement factor H (CFH), in dry AMD patients. The trial, which remains ongoing, is designed to evaluate safety and tolerability, as well as measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers, to inform the late-stage development program.
Second Sight... More
Second Sight Medical (EYES) Announces Proposed Offering, Size not Disclosed
June 22, 2021 4:39 PM EDTSecond Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be... More
